Matthew H Wilson

List of Publications by Year
in descending order

45 papers	2,962 citations	257450 24 h-index	254184 43 g-index
47 all docs	47 docs citations	47 times ranked	3762 citing authors

#	Article	IF	Citations
1	Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury. Kidney International, 2022, 101, 79-91.	5.2	15
2	Gene therapy for kidney disease: targeting cystinuria. Current Opinion in Nephrology and Hypertension, 2022, 31, 175-179.	2.0	3
3	Functional analysis of the catalytic triad of the hAT-family transposase TcBuster. Plasmid, 2021, 114, 102554.	1.4	0
4	Cell-programmed nutrient partitioning in the tumour microenvironment. Nature, 2021, 593, 282-288.	27.8	491
5	Cognate restriction of transposition by piggyBac-like proteins. Nucleic Acids Research, 2021, 49, 8135-8144.	14.5	8
6	Expect the unexpected: piggyBac and lymphoma. Blood, 2021, 138, 1379-1380.	1.4	4
7	Genome Engineering Renal Epithelial Cells for Enhanced Volume Transport Function. Cellular and Molecular Bioengineering, 2020, 13, 17-26.	2.1	7
8	Structural basis of seamless excision and specific targeting by piggyBac transposase. Nature Communications, 2020, 11, 3446.	12.8	53
9	Metformin and Inhibition of Transforming Growth Factor-Beta Stimulate In Vitro Transport in Primary Renal Tubule Cells. Tissue Engineering - Part A, 2020, 26, 1091-1098.	3.1	4
10	CRISPR/Cas9 engineering of albino cystinuria Type A mice. Genesis, 2020, 58, e23357.	1.6	2
11	EGF receptorâ€“mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling. Journal of Cell Biology, 2020, 219, .	5.2	12
12	Metabolic consequences of cystinuria. BMC Nephrology, 2019, 20, 227.	1.8	16
13	Direct reprogramming to human nephron progenitor-like cells using inducible piggyBac transposon expression of SNAI2-EYA1-SIX1. Kidney International, 2019, 95, 1153-1166.	5.2	21
14	Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. Nature Communications, 2018, 9, 1325.	12.8	16
15	Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney. Journal of Visualized Experiments, 2018, , .	0.3	4
16	CRISPR/Cas9 engineering of a KIM-1 reporter human proximal tubule cell line. PLoS ONE, 2018, 13, e0204487.	2.5	7
17	Consider Changing the Horse for Your CAR-T?. Molecular Therapy, 2018, 26, 1873-1874.	8.2	4
18	Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR. EBioMedicine, 2018, 34, 18-26.	6.1	30

#	Article	IF	Citations
19	Kidney-specific transposon-mediated gene transfer in vivo. Scientific Reports, 2017, 7, 44904.	3.3	23
20	Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells. Nucleic Acids Research, 2017, 45, 8411-8422.	14.5	37
21	Temporal self-regulation of transposition through host-independent transposase rodlet formation. Nucleic Acids Research, 2017, 45, 353-366.	14.5	526
22	Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia. Journal of Hematology and Oncology, 2016, 9, 27.	17.0	42
23	Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. PLoS ONE, 2015, 10, e0140744.	2.5	11
24	piggyBac-ing models and new therapeutic strategies. Trends in Biotechnology, 2015, 33, 525-533.	9.3	101
25	Protective Role of Insulin-Like Growth Factor-1 Receptor in Endothelial Cells against Unilateral Ureteral Obstructionâ€“Induced Renal Fibrosis. American Journal of Pathology, 2015, 185, 1234-1250.	3.8	39
26	Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Nucleic Acids Research, 2015, 43, 1770-1782.	14.5	44
27	Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Cytotherapy, 2014, 16, 1257-1269.	0.7	42
28	An adaptable system for improving transposonâ€based gene expression in vivo via transient transgene repression. FASEB Journal, 2013, 27, 3753-3762.	0.5	8
29	Evaluation of Long-term Transgene Expression in piggyBac-Modified Human T Lymphocytes. Journal of Immunotherapy, 2013, 36, 3-10.	2.4	22
30	Hyperactive piggyBac Gene Transfer in Human Cells and In Vivo. Human Gene Therapy, 2012, 23, 311-320.	2.7	94
31	Loss of glutathione Sâ€transferase A4 accelerates obstructionâ€induced tubule damage and renal fibrosis. Journal of Pathology, 2012, 228, 448-458.	4.5	28
32	Comparative Analysis of the Recently Discovered hAT Transposon TcBuster in Human Cells. PLoS ONE, 2012, 7, e42666.	2.5	37
33	Manipulating piggyBac Transposon Chromosomal Integration Site Selection in Human Cells. Molecular Therapy, 2011, 19, 1636-1644.	8.2	66
34	PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. Molecular Therapy, 2011, 19, 2133-2143.	8.2	110
35	Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination. Molecular Therapy, 2011, 19, 2239-2248.	8.2	41
36	piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. Human Gene Therapy, 2010, 21, 427-437.	2.7	124

#	Article	IF	Citations
37	Multiplexed transposon-mediated stable gene transfer in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1343-1348.	7.1	76
38	Designing and Testing Chimeric Zinc Finger Transposases. Methods in Molecular Biology, 2010, 649, 353-363.	0.9	11
39	Combining Mtor Inhibitors with Rapa-Resistant T Cells: a Two-Pronged Approach to Tumor Elimination. Blood, 2010, 116, 2853-2853.	1.4	0
40	PiggyBac Transposon-based Inducible Gene Expression In Vivo After Somatic Cell Gene Transfer. Molecular Therapy, 2009, 17, 2115-2120.	8.2	63
41	Genome-wide Mapping of PiggyBac Transposon Integrations in Primary Human T Cells. Journal of Immunotherapy, 2009, 32, 837-844.	2.4	112
42	Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T Lymphocytes. Journal of Immunotherapy, 2009, 32, 826-836.	2.4	97
43	PiggyBac Transposon-mediated Gene Transfer in Human Cells. Molecular Therapy, 2007, 15, 139-145.	8.2	425
44	Functional zinc finger/sleeping beautytransposase chimeras exhibit attenuated overproduction inhibition. FEBS Letters, 2005, 579, 6205-6209.	2.8	49
45	Mechanisms Regulating the Cell Surface Residence Time of the Î±2A-Adrenergic Receptor. Biochemistry, 2000, 39, 693-700.	2.5	37